← Back

Wire · regulatory

Capricor Plunges On Regulatory Setback As FDA Declines To Approve Deramiocel For Duchenne

Published

21 November 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at rttnews.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

The FDA has declined to approve Capricor's cell therapy drug Deramiocel for treating Duchenne muscular dystrophy, causing a significant drop in the company's stock value.

This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 12 Nov 2026 and 21 Nov 2026.

◆ ◆ The Wire takeaway

You face increased risk entering clinical-stage biotech with FDA setbacks like Capricor's Deramiocel. Re-evaluate your trial design and regulatory strategy now to avoid similar delays.

◆ Coverage

4 sources · first reported 12 Nov 2026 · latest 21 Nov 2026

◆ Related on Wire

◆ Topics

BiotechFDAdrug-approvalbiotechDuchenneregulatory-setback